GlaxoSmithKline PLC is investing $120 million at its manufacturing facility in Upper Merion, Pa., to speed up the production of its pipeline drugs and new medicines for cancer and other specialty diseases.
This investment will bring together manufacturing and research in one facility, reducing the overall time it takes to produce a new medicine, the U.K.-based pharmaceutical giant said in a Sept. 25 press release.
The pharmaceutical company has invested about $400 million in manufacturing facilities in the U.S. since 2017. GlaxoSmithKline operates two research and manufacturing sites in Pennsylvania with about 3,500 employees and a corporate headquarters in Philadelphia with a headcount of more than 1,000 people.
The company's Upper Merion facility was constructed in 1996 and in 2017 GlaxoSmithKline decided to upgrade the plant. It will initially manufacture products that are in the clinical stage and are subject to trial results and regulatory approvals, GlaxoSmithKline noted.
